Substantial progress has been made since the World Health Assembly (WHA) resolved to eradicate poliomyelitis in 1988 (1). Among the three wild poliovirus (WPV) types, type 2 (WPV2) was declared eradicated in 2015, and type 3 (WPV3) has not been reported since 2012 (1). In 2017 and 2018, only Afghanistan and Pakistan have reported WPV type 1 (WPV1) transmission (1). When global eradication of poliomyelitis is achieved, facilities retaining poliovirus materials need to minimize the risk for reintroduction of poliovirus into communities and reestablishment of transmission. Poliovirus containment includes biorisk management requirements for laboratories, vaccine production sites, and other facilities that retain polioviruses after eradication; the initial milestones are for containment of type 2 polioviruses (PV2s). At the 71st WHA in 2018, World Health Organization (WHO) Member States adopted a resolution urging acceleration of poliovirus containment activities globally, including establishment by the end of 2018 of national authorities for containment (NACs) to oversee poliovirus containment (2). This report summarizes containment progress since the previous report (3) and outlines remaining challenges. As of August 2018, 29 countries had designated 81 facilities to retain PV2 materials; 22 of these countries had established NACs. Although there has been substantial progress, intensification of containment measures is needed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132186 | PMC |
http://dx.doi.org/10.15585/mmwr.mm6735a5 | DOI Listing |
Microorganisms
September 2024
Microbac Laboratories, Inc., Sterling, VA 20164, USA.
Safe containment of infectious poliovirus (PV) within Poliovirus-Essential Facilities (PEFs) will require the implementation of reliable PV-inactivation approaches for decontaminating work surfaces. Such approaches should be demonstrated empirically to display adequate efficacy at the use temperature, and the contact times required should be characterized to ensure efficacy. Such efficacy is judged by the ability of the inactivation approach to completely inactivate any PV deposited, with the demonstrated total log reduction in PV titer being as high as empirically achievable.
View Article and Find Full Text PDFVirus Evol
July 2024
Institut Pasteur, Université de Paris Cité, CNRS UMR 3569, Virus sensing and signaling Unit, 28 rue du Dr Roux, Paris 75 015, France.
Polioviruses (PVs) are positive strand RNA viruses responsible for poliomyelitis. Many PVs have been isolated and phenotypically characterized in the 1940s-50s for the purpose of identifying attenuated strains that could be used as vaccine strains. Among these historical PVs, only few are genetically characterized.
View Article and Find Full Text PDFVaccines (Basel)
July 2024
ICMR-National Institute of Immunohematology, Mumbai 400012, India.
Rev Panam Salud Publica
April 2024
Pan American Health Organization Regional Office of the World Health Organization Washington, D.C. United States of America Pan American Health Organization, Regional Office of the World Health Organization, Washington, D.C., United States of America.
The Pan American Health Organization (PAHO) and its Member States have been leading the efforts to eradicate wild poliovirus in the Region of Americas since smallpox's successful elimination in 1971. The region became the first to be certified free of wild poliovirus in 1994. However, in July 2022, an unvaccinated patient with no recent travel history was diagnosed with poliomyelitis in the United States of America.
View Article and Find Full Text PDFPathogens
March 2024
Division of Healthy Environments and Population, Regional Office for the Western Pacific, World Health Organization, Manila 1000, Philippines.
Inactivated poliovirus vaccine (IPV), available since 1955, became the first vaccine to be used to protect against poliomyelitis. While the immunogenicity of IPV to prevent paralytic poliomyelitis continues to be irrefutable, its requirement for strong containment (due to large quantities of live virus used in the manufacturing process), perceived lack of ability to induce intestinal mucosal immunity, high cost and increased complexity to administer compared to oral polio vaccine (OPV), have limited its use in the global efforts to eradicate poliomyelitis. In order to harvest the full potential of IPV, a program of work has been carried out by the Global Polio Eradication Initiative (GPEI) over the past two decades that has focused on: (1) increasing the scientific knowledge base of IPV; (2) translating new insights and evidence into programmatic action; (3) expanding the IPV manufacturing infrastructure for global demand; and (4) continuing to pursue an ambitious research program to develop more immunogenic and safer-to-produce vaccines.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!